Nice move today...http://biz.yahoo.com/ap/071102/millennium_pharma_ahead_of_the_bell.html?.v=1The Cambridge, Mass., company raised its forecast for sales of Velcade to $265 million from $250 million, and said royalty payments will be greater than it expected. Excluding one-time charges, it now forecasts a full-year profit of $40 million to $45 million, or 13 to 14 cents per share, up from $20 million to $30 million.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra